Effect of SEA0400 on Cardiac Mn²⁺ efflux rates, using T₁-mapping Manganese-Enhanced MRI (MEMRI) in a Murine Model

B. Waghorn^{1,2}, Y. Yang², B. Klein², A. Baba³, T. Matsuda³, N. Yanasak², and T. Hu²

¹Nuclear and Radiological Engineering / Medical Physics, Georgia Institute of Technology, Augusta, GA, United States, ²Small Animal Imaging, Department of Radiology, Medical College of Georgia, Augusta, GA, United States, ³Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

Introduction

The Na⁺/Ca²⁺ exchanger (NCX) is an important mechanism for the regulation of intracellular Ca²⁺ concentration (1). Protocols that selectively inhibit this exchanger can have potential therapeutic effects during myocardial ischemic-reperfusion injuries (2). Therefore, it is beneficial to monitor Mn^{2+} which acts as a surrogate marker for Ca^{2+} efflux from the myocardium. The reason for using Mn^{2+} as a Ca^{2+} tracer is due to its T_1 shortening effect. By implementing a T_1 -mapping protocol absolute cardiac T_1 values can be calculated at multiple time points post Mn^{2+} infusion, and the washout effect of the Mn^{2+} relaxivity enhancement can be studied *in-vivo*. In this study, we examine the potential of this technique to probe the effects of the cardiac NCX using SEA0400 (3), a NCX inhibitor. SEA0400 was injected into a murine model and its effect on the washout of the Mn²⁺ enhanced cardiac signal was studied. If this technique proves sensitive enough both SEA0400 and an inotropic agent can be used to quantitatively probe calcium fluxes in-vivo in different cardiac disease models. Methods

Manganese-enhanced MRI experiments were performed in adult male C57Bl/6 mice (7-9 weeks old, 23.2±1.5g). The animals were anesthetized with a mixture of medical air, oxygen (1:1) and isoflurane, and maintained at a heart rate of 463±31 bpm with 1.0-2.7% isoflurane. For the initial temporal washout study a single MnCl₂ concentration of 282.6±6.0 nmoles/g total body weight (BW) was infused into the control mice. All infusions were completed on a surgical bench at a constant rate of 0.6 ml/hr with the aid of a syringe pump. T₁-maps were acquired at various time points post infusion ranging from 0.2 hrs -4 days.

Images were acquired on a 7.0-T, 20-cm horizontal bore BioSpec MRI spectrometer (Bruker Instruments, Billerica, MA) equipped with a micro imaging gradient insert (950 mT/m). Animal setup procedures followed those previously described (4). A 35 mm inner diameter volume coil was used to transmit and receive at ¹H frequency. ECG and respiratory signals were monitored by a physiological monitoring system (SA Instruments, INC.). Both pre-Mn²⁺ and post-Mn²⁺ T₁-map short axis heart images were acquired with an ECG-gated, flow-compensated Look-Locker MRI pulse sequence as previously described (5). The T₁-mapping parameters were as

follows: matrix = 128 x 128; Inter-TE/TR = 2.5 ms/10 sec; slice thickness = 1.0 mm; FOV = $3.0 \times 3.0 \text{ cm}$; NA = 2; inversion time/interval = 9/150 ms; echo images = 50. The total imaging time per T₁-map was approximately 43 minutes. The T₁ value of each pixel was calculated in two steps using a custom written C^{++} program (5). Regional T_1 values were calculated from left ventricular free wall (LVWall) region of interest (ROI) analysis on the calculated T₁-maps using AMIDE (6). In-vivo ΔR_1 values were calculated as (post-Mn²⁺ infusion R_1) – (pre-Mn²⁺ infusion R_1)

In order to further examine individual efflux mechanisms the mice were divided into 2 groups, control and SEA0400. MnCl₂ was infused into the tail vein at a concentration of 190.0±1.0 nmoles/g BW. This concentration has previously been shown to generate a significant signal enhancement while mediating the toxic effects. One hour post Mn²⁺ infusion the SEA0400 mice were injected i.p. with 10 mg/kg SEA0400 (Taisho Pharmaceutical Co. Ltd). T₁-maps were acquired for both groups at times ranging from 0.2-31.9 hrs post Mn^{2+} infusion. A ΔR_1 washout curve was produced as above.



Figure 1. – Example short-axis mouse heart T_1 -maps (a) pre-Mn²⁺ infusion and (b) post-Mn²⁺ infusion. Shown are the left and right ventricles (LV and RV respectively).

Results

Sample cardiac short axis T₁-maps, both pre- and post- Mn²⁺ infusion, are shown in Figure

1. Infusion of 282.6 \pm 6.0 nmoles/g BW MnCl₂ yielded Δ R₁ of approximately 4.5 /sec immediately post infusion. This T₁ shortening effect was rapidly attenuated, with ΔR_1 being reduced to 50% in only about 2.5 hours post infusion, as shown in Figure 2. A similar efflux rate was seen with an infusion concentration of 190.0±1.0 nmoles/g BW, Figures 2 and 3, with an initial ΔR_1 of approximately 3.5 /sec. The linear regression over 4 hours post infusion shows that the two data groups have the same initial rate of efflux (p=0.67) with a slope of -0.48 (/sec)/hr. However, there is a visually delayed signal intensity attenuation as seen by the shift in data points for the two groups. Using the linear regression over the first 4 hours there is a significant intercept shift (p=0.001) corresponding to a 1.2 hour increase in relaxivity enhancement.

Conclusions

This study shows that 50% of the Mn2+ enhanced signal in the LVWall is attenuated within approximately 2.5 post infusion hours at 282.6±6.0 nmoles/g BW MnCl₂. Similar trends have been observed at the infusion concentration of 190.0±1.0 nmoles/g BW MnCl₂. Thus far, the Mn efflux curve is potentially multi-faceted, indicative of the calcium efflux mechanisms. The T1mapping protocol provides a more quantitative means of studying the Mn²⁺ efflux



effect. Shown is the experimental time course post- Mn² infusion, against LVWall $\triangle R_1$, with sample size in parentheses.



(4)

8.0

7.0

mechanism. At this point, by inhibiting the NCX with SEA0400, we have seen a trend in Mn²⁺ efflux modulation. Future work to study the actions of the NCX will be warranted by using various pharmaceutical agents. The implementation of Mn^{2+} efflux could therefore provide a pre-clinical model to examine Ca^{2+} efflux in various disease models.

References

1. Shigekawa M, Iwamoto T., Circulation research 2001;88(9):864-876. 2. Takahashi K, et al., European journal of pharmacology 2003;458(1-2):155-162. 3. Matsuda T, et al., The Journal of pharmacology and experimental therapeutics 2001;298(1):249-256. 4. Hu TC, Pautler RG, MacGowan GA, Koretsky AP., Magn Reson Med 2001;46(5):884-890. 5. Chuang KH, Koretsky A., Magn Reson Med 2006;55(3):604-611. 6. Loening AM, Gambhir SS., Mol Imaging 2003;2(3):131-137.